ArticleInternational journal of retina and vitreous2026
COVID-19-related acute macular neuroretinopathy in China: a retrospective study of 90 cases (152 eyes).
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute macular neuroretinopathy (AMN), a rare retinal disorder, is characterized by mild visual impairment that is associated with macular lesions. AMN cases increased during the coronavirus disease 2019 (COVID-19) pandemic. Chinese ophthalmology clinics have also observed an increase in cases since the end of 2022. We analyzed the clinical and epidemiological characteristics of COVID-19-related AMN cases in China.
methodsThis retrospective study included 90 patients (152 eyes). Information regarding COVID-19-related AMN cases was collected from online consultations and local clinics. Cases were diagnosed using multimodal fundus imaging. Statistical analyses were performed to evaluate clinical features and prognostic characteristics.
resultsMost patients were female (n = 70; 78%) and young (mean age, 28.6 ± 6.0 years). Bilateral AMN lesions were observed in 69% (n = 62) of patients. Most patients (n = 79; 88%) experienced a peak in ocular symptoms on the second to third day after COVID-19 symptoms, following a high fever. The most common ocular symptom was scotomas (n = 63 eyes; 41%). Most eyes (n = 112; 74%) had a baseline best-corrected visual acuity of ≥ 20/40. Among 56 patients (96 eyes) with follow-up durations of 3–15 months, changes in patient-reported visual symptoms were observed, with improvement in 41% of eyes (n = 39), no change in 46% (n = 44), and worsening in 13% (n = 13).
conclusionsRecognizing and addressing COVID-19-related retinal complications, particularly AMN, are important. Follow-up is crucial for monitoring the progression and evolution of visual symptoms and retinal changes over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.